DDInter222 DDInter1938
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) resembles {v} (Compound) Vincristine
Bortezomib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Vincristine
Bortezomib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vincristine
Bortezomib {u} (Compound) upregulates {v} (Gene) GRB10
GRB10 {u} (Gene) is upregulated by {v} (Compound) Vincristine
Bortezomib {u} (Compound) downregulates {v} (Gene) CCNB1
CCNB1 {u} (Gene) is upregulated by {v} (Compound) Vincristine
Bortezomib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PSMD2
PSMD2 {u} (Gene) is upregulated by {v} (Compound) Vincristine
Bortezomib {u} (Compound) downregulates {v} (Gene) B4GAT1
B4GAT1 {u} (Gene) is downregulated by {v} (Compound) Vincristine
Bortezomib {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) PSMB8
PSMB8 {u} (Gene) is downregulated by {v} (Compound) Vincristine
Bortezomib {u} (Compound) upregulates {v} (Gene) UBE2A
UBE2A {u} (Gene) is downregulated by {v} (Compound) Vincristine
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) resembles Vincristine (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) resembles Vincristine (Compound)
Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Vincristine (Compound)
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vincristine (Compound)
Bortezomib (Compound) upregulates GRB10 (Gene) and GRB10 (Gene) is upregulated by Vincristine (Compound)
Bortezomib (Compound) downregulates CCNB1 (Gene) and CCNB1 (Gene) is upregulated by Vincristine (Compound)
Bortezomib (Compound) binds PSMD2 (Gene) and Bortezomib (Compound) upregulates PSMD2 (Gene) and PSMD2 (Gene) is upregulated by Vincristine (Compound)
Bortezomib (Compound) downregulates B4GAT1 (Gene) and B4GAT1 (Gene) is downregulated by Vincristine (Compound)
Bortezomib (Compound) binds PSMB8 (Gene) and Bortezomib (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) is downregulated by Vincristine (Compound)
Bortezomib (Compound) upregulates UBE2A (Gene) and UBE2A (Gene) is downregulated by Vincristine (Compound)